Patents
Literature
Patsnap Eureka AI that helps you search prior art, draft patents, and assess FTO risks, powered by patent and scientific literature data.

9 results about "Gamma secretase" patented technology

Gamma secretase is a multi-subunit protease complex, itself an integral membrane protein, that cleaves single-pass transmembrane proteins at residues within the transmembrane domain. Proteases of this type are known as intramembrane proteases. The most well-known substrate of gamma secretase is amyloid precursor protein, a large integral membrane protein that, when cleaved by both gamma and beta secretase, produces a short 37-43 amino acid peptide called amyloid beta whose abnormally folded fibrillar form is the primary component of amyloid plaques found in the brains of Alzheimer's disease patients. Gamma secretase is also critical in the related processing of several other type I integral membrane proteins, such as Notch, ErbB4, E-cadherin, N-cadherin, ephrin-B2, or CD44.

Treatment of multiple myeloma

The present disclosure provides methods of treating multiple myeloma in a patient in need thereof comprising administering a gamma secretase and a B-cell maturation antigen (BCMA)-directed therapy to the patient.
Owner:SPRINGWORKS THERAPEUTICS INC

Combination therapy with an anti BCMA antibody and a gamma secretase inhibitor

The disclosure concerns a method of treating cancer, especially, such as multiple myeloma, involving the combination of an anti-BCMA (B cell maturation antigen) antibody, Belantamab mafodotin -GSK2857916- and a gamma-secretase inhibitor, e.g., nirogacestat -PF03084014-. The disclosure also relates to dosages, duration of treatment and time lapses between administration of the anti-BCMA antibody and the gamma-secretase inhibitor.
Owner:SPRINGWORKS THERAPEUTICS INC

Methods, therapies and uses for treating cancer

To provide a pharmaceutical composition for treating BCMA-expressing cancer.SOLUTION: Provided is a medicament comprising a first therapeutic agent and a second therapeutic agent for use in treating cancer and / or a cancer-related disease in a subject. In some aspects, the first therapeutic agent is a B-cell maturation antigen (BCMA) - specific therapeutic agent. In some aspects, the second therapeutic agent is an anti-PD-1 antibody, an anti-PD-Ll antibody, an immunomodulator, or a gamma secretase inhibitor (GSI).SELECTED DRAWING: None
Owner:PFIZER INC

Inner ear organoids having improved hair cell differentiation ability and method for producing same

PendingUS20250354113A1Epidermal cells/skin cellsNervous system cellsHL - Hearing lossHair cell differentiation
The present invention relates to a method for producing inner ear organoids having improved hair cell differentiation ability, and the inner ear organoids produced according to the same. The present invention is based on the discovery that treatment with a gamma secretase inhibitor and a Wnt signaling activator during the production of inner ear organoids can promote the differentiation of hair cells, and provides the timing of the treatment with a gamma secretase inhibitor and a Wnt signaling activator at which the amount of hair cells in the inner ear organoids can be maximized. The present technology may be used as a method for increasing the production efficiency of inner ear organoids to be applied in the field of hearing loss treatment.
Owner:AJOU UNIV IND ACADEMIC COOP FOUND

Novel substituted indole derivatives as gamma secretase modulators

UndeterminedPK201200441A0Organic chemistryGamma secretase
Owner:JANSSEN PHARMACEUTICALS INC

Crystal forms of niroxostat and dihydrobromide thereof, and preparation method and application of crystal forms of niroxostat and dihydrobromide thereof

PendingCN121362153AOrganic active ingredientsOrganic chemistryEnzyme Inhibitor DrugsMedicine
The invention relates to a novel crystal form of a compound I and dihydrobromide thereof, a preparation method of the novel crystal form, a pharmaceutical composition containing the crystal form, and application of the crystal form in preparation of gamma secretase inhibitor drugs and drugs for treating sclerofibroma.
Owner:CRYSTAL PHARMA CO LTD

Methods for Treating Respiratory Diseases Characterized by Mucus Hypersecretion

PendingUS20260183306A1DiseaseObstructive chronic bronchitis
The invention therefore provides methods of treating a respiratory disease characterized by mucus hyper-secretion comprising administering to a human patient in need of such treatment a gamma secretase inhibitor (GSI), wherein the administration of a GSI is effective in reducing mucus in such patient's lungs or inhibiting mucus accumulation in said patient's lungs. In some embodiments, the methods of the invention are effective in treating a respiratory disease selected from the group consisting of cystic fibrosis, chronic obstructive pulmonary disease, primary ciliary dyskinesis, chronic bronchitis, asthma, idiopathic and secondary bronchiectasis, bronchiolitis obliterans, idiopathic pulmonary fibrosis, respiratory infection and mucus accumulation in response to infection. Methods of the invention further include methods of treating cystic fibrosis wherein a GSI is administered to a patient being administered or in need of a CFTR modulator, wherein the mucus in such patient's lungs is reduced or mucus accumulation in such patient's lungs is inhibited.
Owner:THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIV

Target and small molecule compounds for neural cell transdifferentiation and methods for neural cell transdifferentiation

PendingCN122648351ATransdifferentiationNeural cell
The present application relates to the field of cell biology and cell therapy, in particular to targets and small molecule compounds for neural cell transdifferentiation. Specifically, the present application relates to a method of transdifferentiating astrocytes into other types of neurons, the method comprising contacting a plurality of astrocytes with a gamma secretase inhibitor and culturing the astrocytes. The present application also relates to the cell population obtained by this method and its therapeutic use.
Owner:INST OF ZOOLOGY CHINESE ACAD OF SCI +1